Track topics on Twitter Track topics that are important to you
IntroductionDelveInsight's, Sensipar API Insight, 2018 report provides product and API manufacturers' details across the globe along with the location. The report gives the clear idea on the country...
The FDA approved generics of Amgen's Sensipar, or cinacalcet hydrochloride, from Cipla and Aurobindo Pharma, creating the fir -More-
Aurobindo remains embroiled in litigation with Amgen on a Sensipar formulation patent, while Cipla settled ahead of bench trial. Generic...
IntroductionDelveInsight's pharmaceuticals report, "Sensipar Drug Insight, 2018" highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location....
The most litigated cases in 2016 and 2017 were over Biogen's MS drug Tecfidera, Amgen's Sensipar and Bristol-Myers Squibb and Pfizer's anticoagulant Eliquis.
Sensipar (cinacalcet) Tablets
These highlights do not include all the information needed to use Sensipar safely and effectively. See full prescribing information for Sensipar. Sensipar (cinacalcet) TabletsInitial U.S. Approval: 20...
The purpose of this research is to study the effects and safety of Sensipar approved by the Food and Drug Administration (FDA) in patients with kidney failure who are being treated with di...
Retrospective chart review to gather information on Sensipar patterns of use and effects on biochemical parameters in renal transplant recipients
Objectives include description of current practices; assessment over time of K/DOQI goals, clinical outcomes, health resource utilization(HRU) and patient reported outcomes (PRO) and the ...
The purpose of this study is to evaluate the effects of cinacalcet (cinacalcet HCl or Sensipar®/Mimpara®) on cardiovascular events and death in chronic kidney disease (CKD) patients with...
The purpose of this study is to compare the proportion of chronic kidney disease (CKD) subjects on dialysis receiving Sensipar® and low dose vitamin D or escalating doses of vitamin D alo...
Sensipar® (cinacalcet HCl) is an innovative, first-in-class, oral therapy indicated to treat hyperparathyroidism (excessive levels of parathyroid hormone) caused by chronic kidney disease; it is appr...
NPS Pharmaceuticals is engaged in the discovery, development and commercialization of therapeutic small molecules and recombinant proteins to treat bone and mineral, gastrointestinal and central nervo...
We have published hundreds of Sensipar news stories on BioPortfolio along with dozens of Sensipar Clinical Trials and PubMed Articles about Sensipar for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sensipar Companies in our database. You can also find out about relevant Sensipar Drugs and Medications on this site too.